← GYRE THERAPEUTICS, INC.

	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Total Revenue	$0	$1.0m	$6k	$2.1m	$20.9m	$7.3m	$794k	$113.5m	$105.8m	$116.6m
Revenue from Contract with Customer, Including Assessed Tax	—	—	—	—	—	—	—	$113.5m	$105.8m	—
Cost of Revenue	—	$445k	$3k	$938k	$9.2m	$3.2m	$347k	$4.6m	$3.9m	$5.4m
Cost of revenues	—	—	—	—	$9.2m	$7.4m	$798k	$4.6m	$3.9m	$5.4m
Gross Profit (derived)	—	$573k	$3k	$1.2m	$11.8m	$4.1m	$447k	$108.8m	$101.9m	$111.2m
Research and development	$11.6m	$12.8m	$21.5m	$43.9m	$53.0m	$68.9m	$13.0m	$13.8m	$12.0m	$13.7m
Operating Expenses	$20.8m	$22.8m	$33.8m	$57.3m	$78.3m	$95.2m	$9.4m	$176.0m	$85.7m	$105.1m
Total operating expenses	$20.8m	$22.8m	$33.8m	$57.3m	$78.3m	$95.2m	$9.4m	$180.7m	$89.6m	$105.1m
Comprehensive income from operations	—	—	—	—	—	—	($614k)	($87.0m)	$16.4m	$12.5m
Operating Income (Loss)	($20.4m)	($21.8m)	($33.8m)	($57.3m)	($57.4m)	($87.9m)	($8.6m)	($67.2m)	$16.2m	$11.5m
Additional Financial Items
Amortization of Intangible Assets	—	—	—	—	—	—	—	$100k	$38k	$576k
Income (Loss) from Continuing Operations before Income Taxes, Domestic	—	—	—	—	—	—	—	—	—	($5.2m)
Preferred Stock Dividends, Income Statement Impact	—	$4	—	—	—	—	—	—	—	—
Selling and marketing	—	—	—	—	—	—	$54.2m	$61.2m	$57.5m	$65.2m
General and administrative	$9.3m	$10.0m	$12.4m	$13.4m	$16.2m	$19.0m	$17.4m	$14.7m	$16.1m	$20.8m
Loss on disposal of assets, net	—	—	—	—	—	—	($57.2m)	—	$66k	$4k
Interest income, net	—	—	—	—	—	—	$726k	$1.0m	$1.5m	$1.7m
Change in fair value of warrant liability	—	—	—	—	—	—	—	($9.3m)	$7.2m	$2.7m
Provision for income taxes	—	—	—	—	—	—	$348k	($8.5m)	($5.3m)	($4.6m)
Foreign currency translation adjustments	—	—	—	—	—	—	($4.9m)	($1.5m)	($1.5m)	$2.6m
Foreign currency translation adjustments attributable to noncontrolling interest	—	—	—	—	—	—	($2.2m)	($647k)	($507k)	$818k
Comprehensive income attributable to noncontrolling interest	—	—	—	—	—	—	($158k)	$6.8m	$5.3m	$5.7m
Comprehensive income attributable to common stockholders	—	—	—	—	—	—	($456k)	($93.8m)	$11.1m	$6.8m
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	—	—	—	($87.9m)	($7.9m)	($77.0m)	$23.2m	$14.4m
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest	—	—	—	—	—	—	$2.0m	($85.5m)	$17.9m	$9.9m
Total income before income taxes	—	—	—	—	—	($87.9m)	($7.9m)	($77.0m)	$23.2m	$14.4m
Net Income (Loss) Attributable to Parent	($16.9m)	($21.6m)	($30.1m)	($55.2m)	($56.2m)	($87.9m)	($8.2m)	($85.5m)	$17.9m	$9.9m
Net Income (Loss) Available to Common Stockholders, Basic	—	($25.5m)	($30.1m)	($55.2m)	($56.2m)	—	$4.3m	($92.9m)	$12.1m	$5.0m
Net Income (Loss) Attributable to Noncontrolling Interest	—	—	—	—	—	—	$2.0m	$7.5m	$5.8m	$4.9m
Net income attributable to noncontrolling interest	—	—	—	—	—	—	$2.0m	$7.5m	$5.8m	$4.9m
Earnings Per Share, Basic	—	—	—	—	—	—	($0.26)	($1.41)	$0.14	$0.06
Earnings Per Share, Diluted	($21.75)	—	—	—	—	—	($0.26)	($1.41)	$0.05	$0.02
Common Stock, Dividends, Per Share, Declared	—	—	—	—	—	—	$0.24	—	—	—
Weighted Average Number of Shares Outstanding, Basic	—	—	—	—	—	—	31.5m	65.8m	85.1m	89.3m
Weighted Average Number of Shares Outstanding, Diluted	—	—	—	—	—	—	31.5m	65.8m	102.3m	103.2m
Research and Development Expense	$11.6m	$12.8m	$21.5m	$43.9m	$53.0m	$68.9m	$13.0m	$13.8m	$12.0m	$13.7m
General and Administrative Expense	$9.3m	$10.0m	$12.4m	$13.4m	$16.2m	$19.0m	$17.4m	$14.7m	$16.1m	$20.8m
Other Nonoperating Income (Expense)	$86k	$261k	$1.6m	($39k)	$659k	($87k)	—	—	($1.7m)	($1.5m)
Costs and Expenses	—	—	—	—	—	—	—	$180.7m	$89.6m	$105.1m
Operating Lease, Expense	—	—	—	$600k	$700k	$1.7m	$1.7m	$500k	$700k	$900k
Selling and Marketing Expense	—	—	—	—	—	—	—	$61.2m	$57.5m	$65.2m
Other expense, net	—	—	—	—	—	—	—	($1.5m)	($1.7m)	($1.5m)
Current Income Tax Expense (Benefit)	—	—	—	—	—	—	—	$9.3m	$6.3m	$5.7m
Interest Income (Expense), Net	—	—	—	—	—	—	—	$1.0m	$1.5m	$1.7m
Interest Income (Expense), Nonoperating, Net	—	—	$2.2m	$2.1m	$561k	$39k	$537k	—	—	—
Income Tax Expense (Benefit)	—	—	—	—	—	—	$348k	$8.5m	$5.3m	$4.6m